An Open-label, Single-Arm, Multicenter, Phase IV Trial to Evaluate the Safety of Firmagon in Androgen Deprivation Therapy in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer

Trial Profile

An Open-label, Single-Arm, Multicenter, Phase IV Trial to Evaluate the Safety of Firmagon in Androgen Deprivation Therapy in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 May 2017

At a glance

  • Drugs Degarelix (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 25 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2019.
    • 25 Apr 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top